Last Updated on December 31, 2023 by The Health Master
New Delhi: Spectrum Pharmaceuticals Inc said that the U.S. Food and Drug Administration (USFDA) declined to approve its experimental lung cancer drug, citing the need for an additional study.
The company now plans to de-prioritize the development of the drug, called poziotinib, and said it was in the process of cutting 75 percent of its research and development workforce.
Spectrum had 164 employees as of Dec 31, 2021.
The health regulator’s decision is in line with an advisory panel’s recommendation to not approve the drug.
USFDA declines to approve expanded use of this Antipsychotic drug
USFDA declines to approve this Urinary Tract Infection Drug
USFDA declines to approve this Anti-seizure drug
USFDA declines to authorise this viral skin disease treatment
USFDA declines pediatric EUA for vaccine Covaxin
USFDA declines to approve Gilead’s HIV drug on this concern
NPPA fixes Retail Price of 40 formulations: November 2022
IPC adds one IP Reference Standard & 20 new impurities to IP 2022
USFDA issues warning letter to Glenmark’s Goa facility
DCGI gives nod to Intranasal C-19 booster dose
USFDA issues Form 483 with 8 observations to Lupin
Drug recall: FDA issues nationwide recall for Ferric Carboxymaltose
Govt issues draft notification to amend NDCTR, 2019
Haryana: Sathi app launched to check Drugs abuse
CDSCO approves 4 more Medical Device Testing Labs (MDTL)
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
